Destiny Pharma chairman to step down; replacement named
Insight Weekly: M&A players predict 2023 activity; SPAC IPOs dip; 2022 capacity retirements up
Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally
Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage
Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share
Destiny Pharma PLC said Nigel Rudd is stepping down as chairman and a member of its board Dec. 31.
Rudd will be replaced by Nick Rodgers, a nonexecutive director of Destiny Pharma, in the chairman role.
Brighton, U.K.-based Destiny Pharma develops and sells medicines for infectious diseases.
